Docoh
Loading...

LGVN Longeveron

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.

LGVN stock data

(
)

Press releases

Pro users get this 30m faster
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline – LGVN
20 Oct 21
NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ:LGVN) and certain of its officers. The
Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)
20 Oct 21
MIAMI, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Longeveron, Boston Beer, Waterdrop, and AppHarvest and Encourages Investors to Contact the Firm
19 Oct 21
NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVN
19 Oct 21
LONGEVERON INC. (NASDAQ: LGVN) CLASS ACTION LAWSUIT FILING DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Longeveron Inc.
19 Oct 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 Aug 21
21 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Longeveron earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Cash on hand (at last report) 16.83M 16.83M 16.83M
Cash burn (monthly) 2.54M 1.69M (positive/no burn)
Cash used (since last report) 9.48M 6.29M n/a
Cash remaining 7.36M 10.54M n/a
Runway (months of cash) 2.9 6.2 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
13 Oct 21 Geoff Green Common stock Buy Acquire P No No 3.81 1,000 3.81K 139,723
13 Oct 21 Rock Soffer Common stock Buy Acquire P No No 3.76 12,000 45.12K 51,757
12 Oct 21 Joshua Hare Common stock Buy Acquire P No No 3.69 2,500 9.23K 7,933,263
12 Oct 21 Rock Soffer Common stock Buy Acquire P No No 3.57 4,000 14.28K 39,757
11 Oct 21 Rock Soffer Common stock Buy Acquire P No No 3.45 3,900 13.46K 35,757
8 Oct 21 Joshua Hare Common stock Buy Acquire P No No 3.39 3,015 10.22K 7,930,763
7 Oct 21 Paul T Lehr Common stock Buy Acquire P No No 3.34 1,750 5.85K 116,366
7 Oct 21 Joshua Hare Common stock Buy Acquire P No No 3.38 1,985 6.71K 7,927,748

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 13 11 +18.2%
Opened positions 5 11 -54.5%
Closed positions 3 0 NEW
Increased positions 5 0 NEW
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 539.29M 536.89M +0.4%
Total shares 78.09M 77.81M +0.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Donald M Soffer 77.73M $536.33M 0.0%
Vanguard 131.26K $1.07M +811.5%
Pura Vida Investments 67.12K $546K NEW
Two Sigma Advisers 52.1K $424K +254.4%
Renaissance Technologies 38.2K $311K NEW
Matrix Asset Advisors 35K $285K +16.7%
Geode Capital Management 14.79K $120K NEW
Janney Montgomery Scott 14K $114K NEW
Private Capital 5K $41K 0.0%
RY Royal Bank Of Canada 3.5K $28K NEW
Largest transactions
Shares Bought/sold Change
Vanguard 131.26K +116.86K +811.5%
Pura Vida Investments 67.12K +67.12K NEW
Renaissance Technologies 38.2K +38.2K NEW
Two Sigma Advisers 52.1K +37.4K +254.4%
Geode Capital Management 14.79K +14.79K NEW
Janney Montgomery Scott 14K +14K NEW
Two Sigma Investments 0 -13.1K EXIT
Matrix Asset Advisors 35K +5K +16.7%
Tower Research Capital 0 -4.88K EXIT
RY Royal Bank Of Canada 3.5K +3.5K NEW

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg

Proxies

No filings